- Sector
- Healthcare
- Industry
- Health Information Services
Highlights
- Market Cap
- $12.84B
- Enterprise Value
- $12.76B
- EPS (TTM)
- A$3.18
- PE Ratio
- 55.19
- PEG Ratio
- 1.44
- Total Revenue (TTM)
- A$425.10M
- Gross Profit (TTM)
- A$372.88M
- EBITDA (TTM)
- A$322.51M
- Year Range
- $74.52 - $218.25
- Target Price
- $155.00
- ROA (TTM)
- 62.38%
- ROE (TTM)
- 85.63%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PMCUF Performance Chart
Pro Medicus Ltd (PMCUF) is down 15.4% since the beginning of the year. At $123 per share, PMCUF is trading 43.8% below its 52-week high of $218. Investors who bought $1,000 worth of PMCUF shares 5 years ago would now be looking at an investment worth $3,062.
Loading charts...
Returns By Period
Pro Medicus Ltd (PMCUF) has returned -15.43% so far this year and -31.80% over the past 12 months.
Pro Medicus Ltd
- 1D
- 3.84%
- 1M
- 33.88%
- YTD
- -15.43%
- 6M
- -12.51%
- 1Y
- -31.80%
- 3Y*
- 42.25%
- 5Y*
- 25.08%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
PMCUF Monthly Returns History
Based on dividend-adjusted daily data since Sep 25, 2017, PMCUF's average daily return is +0.23%, while the average monthly return is +4.29%. At this rate, an investment would double in approximately 1.4 years.
Historically, 62% of months were positive and 38% were negative. The best month was May 2025 with a return of +48.4%, while the worst month was Feb 2026 at -38.6%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 5 months.
On a daily basis, PMCUF closed higher 32% of trading days. The best single day was May 7, 2025 with a return of +30.0%, while the worst single day was Feb 12, 2026 at -23.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.72% | -38.59% | 1.91% | 17.72% | -1.11% | 28.58% | -15.43% | ||||||
| 2025 | 7.64% | -5.85% | -17.28% | -8.75% | 48.37% | 5.11% | 9.64% | -1.52% | 1.38% | -19.07% | -2.14% | -9.19% | -6.07% |
| 2024 | 1.93% | 0.59% | 1.17% | 8.24% | 10.67% | 15.80% | -4.00% | 12.75% | 19.71% | 8.33% | 21.54% | -1.73% | 141.27% |
| 2023 | 29.78% | -11.60% | 6.90% | -4.35% | -8.57% | 11.64% | 7.39% | 2.37% | 9.26% | -0.27% | 11.11% | 13.60% | 81.01% |
| 2022 | -31.61% | -1.19% | 19.74% | -4.96% | -13.31% | -3.42% | 20.17% | 5.74% | -6.69% | 0.54% | 15.69% | -10.00% | -20.09% |
| 2021 | 23.93% | 6.97% | -5.50% | 8.73% | -3.79% | 26.51% | 0.07% | 3.89% | -11.30% | -1.89% | 7.25% | 7.19% | 72.43% |
Benchmark Metrics
Pro Medicus Ltd has an annualized alpha of 67.87%, beta of 0.35, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since September 25, 2017.
- This stock captured 181.62% of S&P 500 Index gains but only 40.03% of its losses - a favorable profile for investors.
- Beta of 0.35 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 67.87%
- Beta
- 0.35
- R²
- 0.02
- Upside Capture
- 181.62%
- Downside Capture
- 40.03%
Return for Risk
Risk / Return Rank
PMCUF ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Pro Medicus Ltd (PMCUF) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PMCUF | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.48 | ||
| Sortino ratioReturn per unit of downside risk | -3.00 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 1.37 | -0.40 |
| Calmar ratioReturn relative to maximum drawdown | -0.49 | 2.78 | -3.28 |
| Martin ratioReturn relative to average drawdown | -0.82 | 12.44 | -13.26 |
Dividends
Dividend History
Pro Medicus Ltd provided a 0.26% dividend yield over the last twelve months, with an annual payout of $0.33 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Dividend | $0.33 | $0.23 | $0.53 | $0.28 | $0.22 | $0.16 |
Dividend yield | 0.26% | 0.15% | 0.34% | 0.43% | 0.61% | 0.36% |
Monthly Dividends
The table displays the monthly dividend distributions for Pro Medicus Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.33 | $0.00 | $0.00 | $0.00 | $0.00 | $0.33 | ||||||
| 2025 | $0.00 | $0.23 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.23 |
| 2024 | $0.00 | $0.17 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.36 | $0.00 | $0.00 | $0.00 | $0.53 |
| 2023 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.16 | $0.00 | $0.00 | $0.00 | $0.28 |
| 2022 | $0.00 | $0.00 | $0.10 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.00 | $0.22 |
| 2021 | $0.08 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.08 | $0.00 | $0.00 | $0.00 | $0.16 |
Dividend Yield & Payout
Dividend Yield
Pro Medicus Ltd has a dividend yield of 0.26%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Pro Medicus Ltd has a payout ratio of 29.81%, which is quite average when compared to the overall market. This suggests that Pro Medicus Ltd strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pro Medicus Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pro Medicus Ltd was 66.06%, occurring on Mar 19, 2020. Recovery took 186 trading sessions.
The current Pro Medicus Ltd drawdown is 43.57%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
COVID crash2020 | -66.06%Mar 2020 | 6mo 22d | 9mo 4d | 1y 3moAug 2019 - Dec 2020 |
2026 bear market2026 | -64.88%Feb 2026 | 7mo 6d | — | 11mo 5dJul 2025 - now |
2025 selloff2025 | -45.65%Apr 2025 | 1mo 10d | 2mo 27d | 4mo 7dFeb 2025 - Jul 2025 |
Bear market2022 | -45.30%Jun 2022 | 9mo 25d | 7mo 21d | 1y 5moAug 2021 - Feb 2023 |
Rate-hike selloffLate 2018 | -31.49%Oct 2018 | 27d | 2mo 18d | 3mo 15dOct 2018 - Jan 2019 |
Drawdown Indicators
| PMCUF | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -66.06% | -56.78% | -9.28% |
Max Drawdown (1Y)Largest decline over 1 year | -64.88% | -9.10% | -55.78% |
Max Drawdown (3Y)Largest decline over 3 years | -64.88% | -18.90% | -45.98% |
Max Drawdown (5Y)Largest decline over 5 years | -64.88% | -25.43% | -39.45% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -43.57% | -1.80% | -41.77% |
Average DrawdownAverage peak-to-trough decline | -16.64% | -10.71% | -5.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 38.69% | 2.03% | +36.66% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pro Medicus Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Pro Medicus Ltd is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for PMCUF, comparing it with other companies in the Health Information Services industry. Currently, PMCUF has a P/E ratio of 55.2. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for PMCUF compared to other companies in the Health Information Services industry. PMCUF currently has a PEG ratio of 1.4. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PMCUF relative to other companies in the Health Information Services industry. Currently, PMCUF has a P/S ratio of 43.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PMCUF in comparison with other companies in the Health Information Services industry. Currently, PMCUF has a P/B value of 47.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PMCUF
Add Pro Medicus Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PMCUF